Proposal Submissions
Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
I-SPY 2 accepts proposals from investigators interested in accessing I-SPY data or clinical specimens for original research. The following information describes the general requirements, application process and review processes. Interested applicants should familiarize themselves with this information prior to submission.